Micro-RNA Profile in Patients With Different Stages of Atherosclerosis According to CTA

The study will be conducted in two phases. Phase one. After signing the informed consent, patients with coronary heart disease, angina pectoris II-IV functional class, who underwent MSCT angiography of the coronary arteries for medical reasons, regulated in the relevant ESC and the Russian Society of Cardiology guidelines, will be included in the study. According to the results of MSCT, the participants will be divided into 4 groups: those with atherosclerotic plaques with signs of instability; those with stable atherosclerotic plaques without marked calcification; those with calcined atherosclerotic plaques; those with no signs of atherosclerosis of the coronary arteries. Plasma samples will be analyzed by microarray, using a cardiospecific set.

Phase two. Validation of the results obtained after the first phase will be performed on a larger sample of patients. Patients after signing an informed consent will also undergo MSCT angiography of coronary arteries and according to its results will be devided in 4 groups. To assess the level of microRNA expression in the blood of patients, real-time reverse transcription-polymerase chain reaction (RT-PCR) will be used.

The expected result of the study. For the first time ever, there will be determined the profile of circulating regulatory RNA in patients who underwent MSCT angiography of coronary arteries. Features of expression of circulating microRNAs will be compared with different severity degrees of the atherosclerotic process based on MSCT criteria. The results will be compared with each other (including the "control" group), which will allow to identify common patterns and specific differences.

Inclusion criteria

• Written informed consent of the patient to participate in the study;
• Age 18-80;
• The presence of medical indications for MSCT angiography of coronary arteries in connection with suspected coronary heart disease.

Exclusion criteria

• Age less than 18 or more than 80;
• Pregnancy, breast-feeding;
• Patients who have not undergone (and do not plan) MSCT coronary angiography;
• Any surgical intervention on the heart in history;
• Severe heart failure (III-IV NYHA classes);
• History of myocardial infarction;
• The body mass index of 35 or more;
• More than twice the ALT and/or AST level;
• The presence of severe somatic pathology (except coronary atherosclerosis);
• Patient's refusal to participate in the study;